key: cord-0962901-qqqu4aw2 authors: Caselli, D.; Chironna, M.; Loconsole, D.; Nigri, L.; Mazzotta, F.; Bonamonte, D.; Aricò, M. title: No evidence of SARS‐Cov‐2 infection by PCR or serology in children with pseudochilblain date: 2020-07-01 journal: Br J Dermatol DOI: 10.1111/bjd.19349 sha: 4ad8cdac9923a902f6c5119ecc32e6fe544565fb doc_id: 962901 cord_uid: qqqu4aw2 Despite its aggressive clinical course, leading to 6.4% fatality rate as of May 25, 2020 (https://qap.ecdc.europa.eu/public/extensions/COVID-19/COVID-19.html), COVID‐19 turned out to be only marginally aggressive in children. In a report from Lombardy, 18/88 COVID‐19 hospitalized adults (20%) had developed cutaneous manifestations: erythematous rash, widespread urticarial, and chickenpox‐like vesicles. Trunk was the main involved region. Itching was low or absent and usually lesions healed in few days. An unexpected outbreak of acute pseudochilblain skin lesions is being reported from different countries and related to COVID‐19. (https://qap.ecdc.europa.eu/public/extensions/COVID-19/COVID-19.html), COVID-19 turned out to be only marginally aggressive in children. 1, 2 In a report from Lombardy, 18/88 COVID-19 hospitalized adults (20%) had developed cutaneous manifestations: erythematous rash, widespread urticarial, and chickenpox-like vesicles. Trunk was the main involved region. Itching was low or absent and usually lesions healed in few days. 3 An unexpected outbreak of acute pseudochilblain skin lesions is being reported from different countries and related to COVID-19. [4] [5] [6] Unfortunately, information about COVID-19 status was available in a minority of cases. In their study of 63 patients, Piccolo et al. report that swab was performed in 11 patients (17%) only and resulted positive in 2 cases (3%); serology was available in 6 cases (9%) and was positive in the 2 patients with positive swab. Nevertheless, the authors stated that "children presenting even with only skin manifestations potentially imputable to COVID-19 should be considered contagious until otherwise proven". 6 In a prospective nationwide consensus study in Spain with 375 cases, Galvan Casas et al. report 71 cases of this type of lesion, of which 41% (29 patients) were PCR positive. The remaining 59% had clinical criteria for COVID-10 (European CDC). The sensitivity analysis comparing those that were PCR positive and those with only clinical criteria showed no difference between groups. Since this study only includes patients confirmed positive by PCR or suspected, the percentage is Accepted Article not comparable with that of other studies that include cases with acral lesions, with or without COVID-19 diagnosis. 4 To clarify this assumed association, we examined 38 consecutive children (median age, 13.5 years), with acute pseudochilblain skin lesions (multifocal and asymmetric purpuric-ecchymotic patches and/or "pernio-like" lesions, ecchymotic lesions on the sole, heel and/or plantar aspect of single toe or dorsal aspect of the hands) referred to our tertiary care, university hospital. Thirty-eight patients were enrolled, all evaluable, 22 (58%) males and 16 (42%) females. Their age ranged between 7 and 18 years (median, 13.5 years); three had an associated condition (Xlinked and coeliac disease, n=1; diabetes mellitus and coeliac disease, n=1; nephrotic syndrome, n=1). Upon specific request, associated symptoms were recorded (but never concurrent) in eight patients (16%): six had fever about 1 month before, and two had diarrhoea. History of autoimmune disorders was found in only six patients (one with ANA positivity), while familial or personal history of coagulation defects was seen in four cases. This article is protected by copyright. All rights reserved The skin lesions were localized on the feet, only in few cases also on the hands, and characterized by multifocal and asymmetric purpuric-ecchymotic patches and/or "pernio-like" lesions. Ecchymotic lesions were observed on the sole, heel and/or plantar aspect of single toe or dorsal aspect of the hands. "Pernio-like" pattern with red-bluish erythematous patches were observed on dorsal aspect of toes and fingers sometimes with superficial skin vesicular-bullous swelling and erosion. The time elapsed between the onset of skin lesions and SARS-CoV-2 infection status evaluation ranged between 3 and 88 days (median, 25 days). In all the study patients, we could not document SARS-CoV-2 infection based on negativity at both, real time-PCR, and serological test for SARS-CoV-2 antibodies, IgM, IgG or IgA. No other pathogens potentially causing the lesions were identified by molecular tests, except for the detection of Mycoplasma pneumoniae in one patient. In conclusion, despite the systematic use of both, molecular and serological assays, we have not found data to support the relationship of the outbreak of pseudochilblain, frequently observed in children and adolescents during the COVID-19 spread, with SARS-CoV-2 infection. Our data do not allow us to say that there is no association due to the absence of PCR (which is only positive in the early stages of the disease) or detectable immunoglobulins (with inconsistent sensitivity and reliability tests). It would be possible to reach this conclusion if we were able to assess the duration of the positive serology and the percentage of affected persons who acquire antibodies, in relation to their age and the intensity of the COVID-19 symptoms, and the percentage of positives in the general population. The use of serology was aimed at giving us the opportunity also to explore the hypothesis that skin alterations appear as a late manifestation of COVID in children and adolescents, when nasopharyngeal swab may test negative. Yet, based on the current knowledge, seronegativity cannot be taken as an absolute marker of non-infection. Clustering of skin lesions during peak pandemic in our region and its quick decline in the last weeks, suggest some non-random association, which someway parallels that suggested for Kawasaki disease 7 . Understanding such inflammatory phenomena in children might provide vital information about immune responses to SARS-CoV-2, relevant both for adults and children, and possibly contribute to clarify why children are usually mildly or not affected by COVID-19. 2019-nCoV: Polite With Children! Pediatr Rep Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group. Children With Covid-19 in Pediatric Emergency Departments in Italy Cutaneous manifestations in COVID-19: a first perspective Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases A new vasculitis at the time of COVID-19 Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients Kawasaki-like disease: emerging complication during the COVID-19 pandemic This article is protected by copyright. All rights reserved